China Pharma Holdings (CPHI) Cash from Operations (2010 - 2026)
China Pharma Holdings (CPHI) posted Cash from Operations of 55292.0 for Q1 2026, down 136.38% on a QoQ basis from 151990.0 in Q4 2025, and up 24.95% year-over-year from 44250.42 in Q1 2025.
China Pharma Holdings (CPHI) Cash from Operations (2010 - 2026) Analysis & Trends
China Pharma Holdings' Cash from Operations history runs 17 years deep, the most recent figure standing at 55292.0 for Q1 2026.
- Quarterly Cash from Operations rose 24.95% year-over-year to 55292.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 166645.0 (up 58.08% YoY) and the FY2025 annual result came in at 148261.0, up 136.51% from the prior year.
- Cash from Operations was 55292.0 for Q1 2026 at China Pharma Holdings, down from 151990.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1007286.0 in Q3 2023 and bottomed at 1468214.0 in Q1 2023.
- A 5-year average of 83666.18 and a median of 55292.0 in 2026 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations soared 1438.41% — and 2025, when it slumped 404.74%.
- China Pharma Holdings' Cash from Operations stood at 584594.0 in 2022, then sank by 103.82% to 22323.0 in 2023, then surged by 1438.41% to 298773.0 in 2024, then sank by 49.13% to 151990.0 in 2025, then tumbled by 136.38% to 55292.0 in 2026.
- Business Quant data shows CPHI's Cash from Operations at 55292.0 in Q1 2026, 151990.0 in Q4 2025, and 236987.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | -55,292.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55,292.00 |
| Mar 31, 2026 | -55,292.00 |
| Dec 31, 2025 | 151,990.00 |
| Dec 31, 2025 | 151,990.00 |
| Sep 30, 2025 | -236,987.00 |
| Sep 30, 2025 | -236,987.00 |
| Jun 30, 2025 | 306,934.00 |
| Jun 30, 2025 | 306,934.00 |
| Mar 31, 2025 | -73,676.00 |
| Mar 31, 2025 | -73,676.00 |
| Dec 31, 2024 | 298,773.00 |
| Dec 31, 2024 | 298,773.00 |
| Sep 30, 2024 | -46,952.00 |
| Sep 30, 2024 | -46,952.00 |
| Jun 30, 2024 | -72,726.00 |
| Jun 30, 2024 | -72,726.00 |
| Mar 31, 2024 | -585,158.00 |
| Mar 31, 2024 | -585,158.00 |
| Dec 31, 2023 | -22,323.00 |
| Dec 31, 2023 | -22,323.00 |